Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

tusamitamab ravtansine (SAR408701)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie, Innovent Biologics, Sanofi

Drug class:

Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

PF-08046048 (4)

PF-08046047 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

›

CEACAM5 positive	Gastric Cancer	CEACAM5 positive	Gastric Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 positive	Lung Cancer	CEACAM5 positive	Lung Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 positive	Colorectal Cancer	CEACAM5 positive	Colorectal Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 expression	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Gastric Cancer	CEACAM5 expression	Gastric Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Solid Tumor	CEACAM5 expression	Solid Tumor	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3
CEACAM5 overexpression	Gastric Cancer	CEACAM5 overexpression	Gastric Cancer	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + SAR408701 Sensitive: C3 – Early Trials pembrolizumab + SAR408701 Sensitive : C3	pembrolizumab + SAR408701 Sensitive: C3 – Early Trials pembrolizumab + SAR408701 Sensitive : C3
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	ramucirumab + SAR408701 Sensitive: C3 – Early Trials ramucirumab + SAR408701 Sensitive : C3	ramucirumab + SAR408701 Sensitive: C3 – Early Trials ramucirumab + SAR408701 Sensitive : C3
CEACAM5 expression	Pancreatic Cancer	CEACAM5 expression	Pancreatic Cancer	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D